Advances in the systemic treatment of triple-negative breast cancer.
Advances in the systemic treatment of triple-negative breast cancer.
Curr Oncol. 2018 Jun;25(Suppl 1):S142-S150
Authors: Lebert JM, Lester R, Powell E, Seal M, McCarthy J
Abstract
Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic treatment of triple-negative breast cancer in the neoadjuvant, adjuvant, and metastatic settings. In this review, we discuss evidence for the potential benefit of neoadjuvant platinum-based chemotherapy, adjuvant combination chemotherapy with weekly paclitaxel, and BRCA mutation-directed therapy in the metastatic setting. The role for adjuvant capecitabine in patients who do not achieve a pathologic complete response with neoadjuvant chemotherapy is reviewed. Future directions and data concerning novel targeted agents are reviewed, including the most recent data on parp [poly (adp-ribose) polymerase] inhibitors, antiandrogen agents, and immunotherapy.
PMID: 29910657 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Xeloda